Akebia Therapeutics Inc expected to post a loss of 8 cents a share - Earnings Preview

Akebia Therapeutics

03/05/2024 16:33

* Akebia Therapeutics Inc  AKBA.OQ   AKBA.O  is expected
to show a
rise in quarterly revenue when it reports  results on May 9 for
the period ending March 31 2024
    * The Cambridge Massachusetts-based  company is expected to
report
a 14.9% increase in revenue to $46.087 million from $40.13
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Akebia Therapeutics Inc
is for
a loss of 8 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Akebia
Therapeutics Inc is $5.00​, above​ its last closing price
of $1.30. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  -0.04       -0.04      0.00      Beat    100
 Sep. 30 2023  -0.07       -0.08      -0.08     Met     5.9
 Jun. 30 2023  -0.02       -0.02      -0.06     Missed  -140​
 Mar. 31 2023  -0.15       -0.15      -0.14     Beat    6.7
 ​​Dec.        -0.27       -0.19      -0.04     Beat    78.6
 31 2022                                                
 Sep. 30 2022  -0.15       -0.15      -0.28     Missed  -86.7​
 Jun. 30 2022  -0.31       -0.31      0.23      Beat    173.2
 Mar. 31 2022  -0.28       -0.29      -0.35     Missed  -21.4
 This summary was machine generated May 3 at 15:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)